Health authorities in the United Kingdom have issued an urgent recall for specific batches of paracetamol after reports of possible contamination. The Medicines and Healthcare products Regulatory Agency (MHRA) is acting swiftly to ensure public safety while investigations continue.
Recalled Batch Numbers
The recall affects two prescription-only batches of Paracetamol 500mg Tablets produced by Chelonia Healthcare Limited. The specific batch numbers are:
- 2312010 (expiry date: 30 November 2027, first distributed 14 April 2025)
- 2312011 (expiry date: 31 November 2027, first distributed 15 May 2025)
These batches are supplied in pots of 100 tablets and are only available via prescription through pharmacies.
Reason for Recall
The recall was prompted after healthcare professionals reported finding discoloured tablets in some containers. While the issue was initially identified in batch 2312010, batch 2312011 is being recalled as a precaution while further analysis is conducted. The discolouration has raised concerns about potential contamination, although there have been no confirmed reports of harm to patients so far. Contaminated paracetamol tablets can pose health risks, particularly if taken in large doses or over an extended period. Research has shown that prolonged use of paracetamol can increase the risk of gastrointestinal, cardiovascular, and renal complications, especially in older adults.
Guidance for Patients and Healthcare Professionals
Patients are being urged to:
- Check the label on their paracetamol bottles for the affected batch numbers.
- Return any medication from these batches to their pharmacy.
- Contact their pharmacist or healthcare provider if they notice any discoloured tablets or experience adverse reactions.
Healthcare professionals have been instructed to immediately stop supplying these batches, quarantine any remaining stock, and return it to their supplier.
Ongoing Investigation
The MHRA and Chelonia Healthcare Limited are continuing their investigation into the cause and extent of the contamination. Patients who experience any adverse reactions or have concerns about their medication are advised to seek medical attention and report any suspected reactions via the MHRA Yellow Card scheme.It’s important to pay attention to any medication you may have under the Chelonia Healthcare Ltd name.
This recall underscores the importance of robust pharmaceutical quality controls and the rapid response of regulatory agencies to potential health risks. Further updates will be provided as the investigation progresses.
